Displaying 21 - 40 of 589 tests
AML Add-On Flow Panel
Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD3, cCD22, cCD79, CD11b, CD123, CD34, CD45, CD117, cMPO, and nTdT (10 markers).
Flow Cytometry
AML Favorable-Risk Panel
Probes: RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) Disease(s): Acute myeloid leukemia Probes may be ordered separately.
FISH
AML FISH Panel (New York)
Probes: 5q-, -5 (5p15.2, 5q33-34) | 7q-, -7 (7q31, Cen 7) | Trisomy 8 (Cen 8) | MLL (11q23) | RUNX1T1/RUNX1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) Probes may be ordered separately. Disease(s): AML Note: STAT processing is available by request for PML-RARA. Note STAT along
FISH
AML Follow-Up Flow Panel
Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are
Flow Cytometry
AML Non-Favorable Risk FISH Panel
Probes: RPN1, MECOM (3q21, 3q26.2) | 5q-, -5 (5p15, 5q31, 5q33 | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | DEK/NUP214 (CAN) t(6;9) | MLL (11q23) | ETV6 (12p13) | 17p- (TP53 17p13.1, NF1 17q11.2) | Probes may be ordered separately. Disease(s): Acute myeloid leukemia
FISH
AML Reflex Panel
Routine cytogenetics with automatic addition of the NeoTYPE™ AML Prognostic Profile when cytogenetics results show intermediate risk including normal cytogenetics, +6, +8, -Y, or del(12p).
Molecular
AML Standard FISH Panel
Probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | MLL (11q23) | 20q- (20q12, 20qter) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) Probes may be ordered separately except +8 and 20q- which are combined. Disease(s): Acute myeloid
FISH
Amyloid A & Amyloid P
Amyloid A and P react with amyloid deposits in many tissues. When accompanied by Congo Red, Amyloid A and P can be used to distinguish primary and secondary amyloidosis. Because these stains are interpreted in context of each other and Congo Red, testing options available to global and tech-only
Immunohistochemistry (IHC)
Androgen Receptor Mutation Analysis
Bi-directional Sanger sequencing of the gene Androgen Receptor is performed using PCR primers designed to target hotspot mutations in exons 4, 5 and 8.
Molecular
Annexin A1
Annexin A1 (ANXA1), a gene related to phagocytosis, is found to be one of the most highly upregulated genes in hairy cell leukemia. Annexin A1 is strongly expressed on the cell membrane of 97% of hairy cell leukemia cases. Although Annexin A1 is negative in normal B-cells or B-cell tumors other than
Immunohistochemistry (IHC)
API2/MALT1 t(11;18)
Probes: API2/MALT1 t(11;18) Disease(s): MALT lymphoma, NHL
FISH
AR
Androgen receptor (AR) is responsible for the regulation of the growth of the prostate epithelial cells. In untreated prostate carcinoma, AR positive cells are more likely to be responsive to hormonal therapy. In patients with hormone refractory prostate carcinoma, the presence of AR has a negative
Immunohistochemistry (IHC)
Arginase 1
Arginase 1 (ARG1), also known as liver arginase, is a binuclear manganese metalloenzyme. ARG1 is abundantly expressed in liver and represents a sensitive and specific marker of benign and malignant hepatocytes that may be a useful diagnostic tool in routine surgical pathology practice.
Immunohistochemistry (IHC)
ASXL1 Mutation Analysis
Bi-directional sequencing of the majority of exons 13 and 14 of ASXL1, corresponding to amino acids 406-1396.
Molecular
ATRX
ATRX mutations predominantly occur in grade II/III astrocytoma and secondary glioblastoma multiforme (GBM) brain tumors. ATRX loss defines a subgroup of astrocytic tumors with a favorable prognosis.
Immunohistochemistry (IHC)
ATRX Mutation Analysis
Bi-directional Sanger sequencing of ATRX is performed using PCR primers designed to target hotspot mutations in exons 8-10, 12-15, 17, 18, 21, 22, 26, 30-32, and 35.
Molecular
B-ALL Add-On Flow Panel
Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD3, cCD22, cCD79a, CD10, CD19, CD34, CD45, cMPO, and nTdt (9 markers).
Flow Cytometry
B-ALL Follow-Up Flow Panel
Available only as tech-only. Global clients, please refer to the B-ALL MRD Flow Panel . Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Tech-only clients who push cases to global will be asked to provide previous flow cytometry report, previous
Flow Cytometry
B-ALL MRD Flow Panel
Available as global test only. Markers are CD3, CD9, CD10, CD13/CD33, CD19, CD20, CD34, CD38, CD45, CD58, CD71, and Syto16 (13 markers; Syto16 is not reported). This panel can detect MRD at the 0.01% level.
Flow Cytometry
B-Cell Gene Rearrangement
Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides recognizing the Vk, intragenic and Jk regions. Testing is approved for specimens from the state of
Molecular